[SCHEDULE 13G/A] Dynavax Technologies Corporation SEC Filing
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP and individual David Kroin report shared beneficial ownership of 15,726,349 shares of Dynavax Technologies Corporation common stock, representing 13.41% of the 117,267,482 shares outstanding cited in the filing. The filing is Amendment No. 2 to a prior Schedule 13G/13D series and states the Reporting Persons are eligible to report on Schedule 13G under Rule 13d-1(h), replacing the prior Schedule 13D disclosures.
The cover-page details show the Reporting Persons have no sole voting or dispositive power and only shared voting and dispositive power over the reported shares.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP e l'individuo David Kroin dichiarano la propriet脿 beneficiaria congiunta di 15.726.349 azioni ordinarie di Dynavax Technologies Corporation, pari al 13,41% delle 117.267.482 azioni in circolazione indicate nel deposito. Il documento 猫 l'Emendamento n. 2 a una precedente serie di Schedule 13G/13D e precisa che le Persone che effettuano la segnalazione sono ammissibili a utilizzare il Schedule 13G ai sensi della Regola 13d-1(h), sostituendo le precedenti disclosure incluse nello Schedule 13D.
La pagina di copertina indica che le Persone che segnalano non posseggono potere di voto o di disposizione esclusivo e detengono soltanto potere di voto e di disposizione condiviso sulle azioni segnalate.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP y la persona f铆sica David Kroin informan propiedad beneficiaria compartida de 15.726.349 acciones ordinarias de Dynavax Technologies Corporation, que representan el 13,41% de las 117.267.482 acciones en circulaci贸n citadas en la presentaci贸n. La presentaci贸n es la Enmienda n.潞 2 a una serie previa de Schedule 13G/13D y declara que las Personas Informantes son elegibles para presentar en el Schedule 13G conforme a la Regla 13d-1(h), reemplazando las divulgaciones anteriores del Schedule 13D.
La portada muestra que las Personas Informantes no tienen poder exclusivo de voto ni de disposici贸n y solo poseen poder compartido de voto y de disposici贸n sobre las acciones informadas.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP 氚� 臧滌澑 David Kroin電� Dynavax Technologies Corporation 氤错喌欤� 15,726,349欤检棎 雽�頃� 瓿惦彊 靾橃澋鞝� 靻岇湢毳� 氤搓碃頄堨溂氅�, 鞚措姅 鞝滌稖靹滊鞐� 旮办灛霅� 齑� 氚滍枆欤检嫕 117,267,482欤检潣 13.41%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 鞝滌稖靹滊姅 鞚挫爠 Schedule 13G/13D 瓿勳棿鞐� 雽�頃� 靾橃爼靹�(靾橃爼氩堩樃 2)搿�, 氤搓碃 雼轨偓鞛愲摛鞚� 攴滌箼 13d-1(h)鞐� 霐半澕 Schedule 13G搿� 氤搓碃頃� 鞛愱博鞚� 鞛堨潓鞚� 氇呾嫓頃橃棳 鞚挫爠鞚� Schedule 13D 瓿奠嫓毳� 雽�觳错暕雼堧嫟.
響滌 韼橃澊歆�鞐愲姅 氤搓碃 雼轨偓鞛愲摛鞚� 氤搓碃霅� 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓岇澊雮� 觳橂秳甓岇潉 氤挫湢頃橃 鞎婌潓鞚� 氚濏瀳瓿�, 鞓れ 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岆 氤挫湢頃橁碃 鞛堨潓鞚� 旮办灛頃橁碃 鞛堨姷雼堧嫟.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP et l'individu David Kroin d茅clarent la propri茅t茅 b茅n茅ficiaire conjointe de 15 726 349 actions ordinaires de Dynavax Technologies Corporation, repr茅sentant 13,41% des 117 267 482 actions en circulation mentionn茅es dans le d茅p么t. Le dossier constitue l'Amendement n掳2 脿 une s茅rie ant茅rieure de Schedule 13G/13D et pr茅cise que les personnes d茅clarante sont 茅ligibles 脿 d茅clarer sur le Schedule 13G en vertu de la r猫gle 13d-1(h), rempla莽ant ainsi les divulgations ant茅rieures du Schedule 13D.
La page de couverture indique que les personnes d茅clarante n'ont aucun pouvoir de vote ou de disposition exclusif et ne d茅tiennent que un pouvoir de vote et de disposition partag茅 sur les actions d茅clar茅es.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP und die Privatperson David Kroin melden gemeinschaftliches wirtschaftliches Eigentum an 15.726.349 Stammaktien der Dynavax Technologies Corporation, was 13,41% der in der Einreichung angegebenen 117.267.482 ausstehenden Aktien entspricht. Die Einreichung ist 脛nderung Nr. 2 zu einer fr眉heren Schedule 13G/13D-Serie und erkl盲rt, dass die meldenden Personen nach Regel 13d-1(h) berechtigt sind, auf Schedule 13G zu berichten, womit die fr眉heren Schedule 13D-Angaben ersetzt werden.
Aus der Titelseite geht hervor, dass die meldenden Personen keine alleinige Stimm- oder Verf眉gungsmacht innehaben, sondern lediglich gemeinsame Stimm- und Verf眉gungsmacht 眉ber die gemeldeten Aktien aus眉ben.
- Material disclosure of a 13.41% stake in DVAX provides transparency to the market
- Amendment replaces prior Schedule 13D and clarifies current reporting status under Rule 13d-1(h)
- None.
Insights
TL;DR: A coordinated investor group discloses a >13% passive stake, filed as a Schedule 13G amendment replacing prior 13D filings.
The filing documents a meaningful minority holding of 15,726,349 shares (13.41%). The Reporting Persons state shared voting and dispositive power and assert the holdings are not for the purpose of changing control. The restatement from a Schedule 13D to a Schedule 13G under Rule 13d-1(h) signals that the group considers its position passive per the rule's conditions. This is a material ownership disclosure but contains no operational, financial performance or transaction details.
TL;DR: Governance disclosure shows coordinated ownership but affirms passive intent; no control actions are declared.
The reporting trio鈥攁n investment fund, its adviser/partner structure, and an individual鈥攅ach report identical aggregate holdings and classification of authority as shared rather than sole. The certification language explicitly states the securities were not acquired to influence control. This filing is important for shareholders and proxy considerations because a >5% stake obligates transparency, yet it disclaims activist intent and lists no group dissolution or additional arrangements.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP e l'individuo David Kroin dichiarano la propriet脿 beneficiaria congiunta di 15.726.349 azioni ordinarie di Dynavax Technologies Corporation, pari al 13,41% delle 117.267.482 azioni in circolazione indicate nel deposito. Il documento 猫 l'Emendamento n. 2 a una precedente serie di Schedule 13G/13D e precisa che le Persone che effettuano la segnalazione sono ammissibili a utilizzare il Schedule 13G ai sensi della Regola 13d-1(h), sostituendo le precedenti disclosure incluse nello Schedule 13D.
La pagina di copertina indica che le Persone che segnalano non posseggono potere di voto o di disposizione esclusivo e detengono soltanto potere di voto e di disposizione condiviso sulle azioni segnalate.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP y la persona f铆sica David Kroin informan propiedad beneficiaria compartida de 15.726.349 acciones ordinarias de Dynavax Technologies Corporation, que representan el 13,41% de las 117.267.482 acciones en circulaci贸n citadas en la presentaci贸n. La presentaci贸n es la Enmienda n.潞 2 a una serie previa de Schedule 13G/13D y declara que las Personas Informantes son elegibles para presentar en el Schedule 13G conforme a la Regla 13d-1(h), reemplazando las divulgaciones anteriores del Schedule 13D.
La portada muestra que las Personas Informantes no tienen poder exclusivo de voto ni de disposici贸n y solo poseen poder compartido de voto y de disposici贸n sobre las acciones informadas.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP 氚� 臧滌澑 David Kroin電� Dynavax Technologies Corporation 氤错喌欤� 15,726,349欤检棎 雽�頃� 瓿惦彊 靾橃澋鞝� 靻岇湢毳� 氤搓碃頄堨溂氅�, 鞚措姅 鞝滌稖靹滊鞐� 旮办灛霅� 齑� 氚滍枆欤检嫕 117,267,482欤检潣 13.41%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 鞝滌稖靹滊姅 鞚挫爠 Schedule 13G/13D 瓿勳棿鞐� 雽�頃� 靾橃爼靹�(靾橃爼氩堩樃 2)搿�, 氤搓碃 雼轨偓鞛愲摛鞚� 攴滌箼 13d-1(h)鞐� 霐半澕 Schedule 13G搿� 氤搓碃頃� 鞛愱博鞚� 鞛堨潓鞚� 氇呾嫓頃橃棳 鞚挫爠鞚� Schedule 13D 瓿奠嫓毳� 雽�觳错暕雼堧嫟.
響滌 韼橃澊歆�鞐愲姅 氤搓碃 雼轨偓鞛愲摛鞚� 氤搓碃霅� 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓岇澊雮� 觳橂秳甓岇潉 氤挫湢頃橃 鞎婌潓鞚� 氚濏瀳瓿�, 鞓れ 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岆 氤挫湢頃橁碃 鞛堨潓鞚� 旮办灛頃橁碃 鞛堨姷雼堧嫟.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP et l'individu David Kroin d茅clarent la propri茅t茅 b茅n茅ficiaire conjointe de 15 726 349 actions ordinaires de Dynavax Technologies Corporation, repr茅sentant 13,41% des 117 267 482 actions en circulation mentionn茅es dans le d茅p么t. Le dossier constitue l'Amendement n掳2 脿 une s茅rie ant茅rieure de Schedule 13G/13D et pr茅cise que les personnes d茅clarante sont 茅ligibles 脿 d茅clarer sur le Schedule 13G en vertu de la r猫gle 13d-1(h), rempla莽ant ainsi les divulgations ant茅rieures du Schedule 13D.
La page de couverture indique que les personnes d茅clarante n'ont aucun pouvoir de vote ou de disposition exclusif et ne d茅tiennent que un pouvoir de vote et de disposition partag茅 sur les actions d茅clar茅es.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP und die Privatperson David Kroin melden gemeinschaftliches wirtschaftliches Eigentum an 15.726.349 Stammaktien der Dynavax Technologies Corporation, was 13,41% der in der Einreichung angegebenen 117.267.482 ausstehenden Aktien entspricht. Die Einreichung ist 脛nderung Nr. 2 zu einer fr眉heren Schedule 13G/13D-Serie und erkl盲rt, dass die meldenden Personen nach Regel 13d-1(h) berechtigt sind, auf Schedule 13G zu berichten, womit die fr眉heren Schedule 13D-Angaben ersetzt werden.
Aus der Titelseite geht hervor, dass die meldenden Personen keine alleinige Stimm- oder Verf眉gungsmacht innehaben, sondern lediglich gemeinsame Stimm- und Verf眉gungsmacht 眉ber die gemeldeten Aktien aus眉ben.
FAQ
What stake in Dynavax (DVAX) do the Reporting Persons disclose?
Do the Reporting Persons claim control of Dynavax (DVAX)?
Which entities filed this Schedule 13G/A for DVAX?
What change does Amendment No. 2 make to prior filings for DVAX?
As of what date is the ownership information reported?
